期刊
MAYO CLINIC PROCEEDINGS
卷 92, 期 6, 页码 995-1004出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2017.01.010
关键词
-
The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers' understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically. (C) 2017 Mayo Foundation for Medical Education and Research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据